NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 107 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.00 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $57,442,000 | -13.9% | 3,766,666 | 0.0% | 39.74% | -8.2% |
| Q4 2021 | $66,708,000 | -15.7% | 3,766,666 | 0.0% | 43.30% | -1.9% |
| Q3 2021 | $79,175,000 | +6.6% | 3,766,666 | 0.0% | 44.14% | +549.2% |
| Q2 2021 | $74,279,000 | -32.2% | 3,766,666 | 0.0% | 6.80% | -35.4% |
| Q1 2021 | $109,497,000 | -4.0% | 3,766,666 | 0.0% | 10.53% | -82.5% |
| Q4 2020 | $114,111,000 | +90.4% | 3,766,666 | 0.0% | 60.06% | +20.4% |
| Q3 2020 | $59,928,000 | -19.4% | 3,766,666 | 0.0% | 49.90% | +3.6% |
| Q2 2020 | $74,354,000 | +60.1% | 3,766,666 | 0.0% | 48.16% | +2.9% |
| Q1 2020 | $46,443,000 | -33.3% | 3,766,666 | 0.0% | 46.79% | -11.6% |
| Q4 2019 | $69,646,000 | +33.5% | 3,766,666 | -0.0% | 52.94% | +21.2% |
| Q3 2019 | $52,168,000 | -5.4% | 3,766,667 | 0.0% | 43.68% | +14.2% |
| Q2 2019 | $55,144,000 | – | 3,766,667 | – | 38.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |